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Background Notch ligands enhance ex vivo expansion of hematopoietic stem cells (HSCs). But to use Notch ligands in HSC
therapies of human diseases, efforts are required to improve ex vivo expansion efficiency and in vivo transplant engraftment.
Design and methods We designed and produced an endothelium-targeted soluble Notch ligand, the DSL domain of Delta-like
1 fused with a RGD motif (D1R), and examined the effects of this protein on HSCs ex vivo and in vivo.
Results D1R efficiently promoted ex vivo expansion of both mouse bone marrow (BM) and human umbilical cord blood HSCs.
HSCs expanded with D1R up-regulated many of the stemness-related genes, and showed high BM engraftment efficacy with
long-term repopulation capacity after transplantation. Moreover, in vivo administration of D1R increased the number of BM
HSCs in mice, and facilitated BM recovery of mice after irradiation. Injection of D1R significantly improved HSC engraftment
and myeloid recovery after BM transplantation in irradiated mice. D1R enhanced HSC engraftment not only in BM, but also in
the liver and spleen after BM transplantation in mice. D1R induced the formation of compact cell clusters containing the
transplanted HSCs in close contact with endothelial cells, reminiscent of HSC niches, in the liver and spleen.
Conclusions D1R might be applied in improving both HSC expansion ex vivo and HSC engraftment in vivo in transplantation.
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http://dx.doi.org/10.1016/j.scr.2013.04.008IntroductionTransplantation of hematopoietic stem cells (HSCs) is an
effective, sometimes the only, therapy for many human
diseases. However, the rareness of HSCs, either derived
from bone marrow (BM) or umbilical cord blood (UCB), has
hindered wide spread application and the effectiveness of
Figure 1 mD1R efficiently expanded murine HSCs in vitro. Mouse KSL cells were cultured on HUVECs + m5GF with PBS, mD1S or
mD1R for 7 days. (A) The total numbers of hematopoietic cells were counted. (B, C) The cells were analyzed by FACS and the numbers
of KSL cells after the culture were calculated (C). (D) Colony-forming assay. The colonies of different lineages were counted and
presented as CFU/1000 cultured cells. (E, F) Expansion of KSL cells required endocytosis-mediated Notch activation. KSL cells were
expanded with mD1R as above in the presence of DMSO, GSI or Dynasore (Dyna). The total cell number (E) and the number of KSL cells
(F) were compared (n = 4). (G–I) Gene expression profiles were compared between KSL cells expanded with PBS and mD1R by using
gene chip hybridization. Hierarchical clustering of differentially expressed genes is shown (G). Some of the genes with HSC specificity
(H) and functionally involved in HSCs (I) were confirmed by real time RT-PCR. Bars = means ± s.d. *P b 0.05, #P b 0.05, **P b 0.01.
694 D.-M. Tian et al.this therapy (Weissman, 2000; Kelly et al., 2010; Delaney
et al., 2010a; Dahlberg et al., 2011). HSCs are normally
accommodated in stem cell niches, which involve several
types of cells including endothelial cells (ECs) (Wilson and
Trumpp, 2006; Morrison and Spradling, 2008). These cells
provide paracrine factors and direct cell–cell interaction
signals in temporospatial specific manners, to maintain thestemness as well as the proliferation and differentiation of
HSCs (Blank et al., 2008). Attempts have beenmade to employ
these signaling molecules and pathways to expand HSC ex vivo
and enhance HSC engraftment in vivo in transplantation (Kelly
et al., 2010; Delaney et al., 2010a; Dahlberg et al., 2011).
The Notch pathway plays a critical role in regulating the
proliferation and differentiation of stem and progenitor cells
695ECound Dll1 promotes HSC expansion & engraftmentincluding HSCs during development (Bigas and Espinosa,
2012; Pajcini et al., 2011). In mammals, the canonical Notch
pathway is composed of five ligands (Delta-like [Dll] 1, 3, 4,
Jagged 1, 2), four Notch receptors (Notch1–4), the transcription
factor RBP-J, and the downstream effectors such as the Hairy
and enhancer of Split (Hes) family members. The Notch ligand–
receptor interaction mediated by the Delta-Serrate-Lag-2
(DSL) domain of the ligands triggers proteolytic cleavages of
the receptors, resulting in the endocytosis of the ligands in
signal-sending cells, and the release of Notch intracellular
domain (NICD) in signal-accepting cells. NICD associates
with RBP-J and transactivates downstream genes involved in
development (Gridley, 2010).
Notch receptors and ligands are expressed by BM stromal
and hematopoietic cells (Walker et al., 2001; Singh et al.,
2000). Although Notch signaling is essential for the segregation
of HSCs during embryonic definitive hematopoiesis (Varnum-
Finney et al., 2011; Kumano et al., 2003; Burns et al., 2005;
Robert-Moreno et al., 2005), its role in adult HSCs is contro-
versial (Mancini et al., 2005; Maillard et al., 2008; Duncan
et al., 2005; Stier et al., 2002). Despite these inconsistencies,Figure 2 Repopulation of lethally irradiated mice with expande
sorted from mouse BM (Day 0) or cells expanded ex vivo, labeled wit
the recipients were analyzed by FACS 3 or 24 h after the transfusion
cells) from C57BL/6J-GFP mice expanded with HUVECs + m5GF plus P
mice along with BM cells (2 × 105) from C57BL/6J mice. The periphe
post transplantation. The number of transplanted cells was plotted a
the frequency of repopulating units (n = 10). (C–E) The peripheral b
FACS 16 weeks post the transplantation (C). The percentages of total
compared (n = 10). Bars = means ± s.d. *P b 0.05, **P b 0.01.however, a large body of evidence has demonstrated that
activating Notch signaling facilitates HSC expansion ex vivo
(Mayani, 2010). Expression of NICD in murine hematopoietic
precursors results in immortalization of HSCs and enhanced
HSC self-renewal (Stier et al., 2002; Varnum-Finney et al.,
2000a). Several reports have shown that soluble Notch ligands
could induce HSC expansion ex vivo (Varnum-Finney et al.,
2003; Suzuki et al., 2006; Ohishi et al., 2002; Karanu et al.,
2001; Han et al., 2000). Meanwhile, a requirement for ligand
immobilization to activate Notch signaling for HSC expansion
has been demonstrated (Varnum-Finney et al., 2000b; Lauret
et al., 2004). Other studies have shown the ligand selectiv-
ity, dose-dependency, and the requirement of supporting
ECs in HSC expansion ex vivo (Delaney et al., 2005a; Lahmar
et al., 2008; Vas et al., 2004; Butler et al., 2010). Recently,
significantly reduced average time of neutropenia has been
shown in a phase I clinical trial of transplantation using
human CD34+ cells expanded with the immobilized Delta 1
(Delaney et al., 2010b; North and Goessling, 2010).
However, it has been difficult to manipulate Notch signaling
for therapeutic purposes in vivo. Non-specific interventions ofd mouse HSCs. (A) Homing efficiency. KSL cells (2 × 105) were
h DiI and transfused into lethally irradiated mice. BM cells from
(n = 6). (B) LD-CRU assay. Hematopoietic cells (100, 500, 1000
BS or mD1R were transplanted into lethally irradiated C57BL/6J
ral blood cells of the recipients were analyzed by FACS 16 weeks
gainst the percentage of mice without engraftment to determine
lood cells of the mice (1000 cells group) in (B) were analyzed by
GFP+ cells (D) as well as GFP+ cells of different lineages (E) were
696 D.-M. Tian et al.Notch signal in vivo might result in unexpected adverse
effects, because Notch signal exists universally in almost
all types of cells. Moreover, effective triggering of Notch
receptors requires the endocytosis of Notch ligands (Fortini
and Bilder, 2009; Meloty-Kapella et al., 2012; Hicks et al.,2002). Here, we have developed a novel fusion protein, D1R,
which is composed of the DSL domain of Dll1 and an arginine–
glycine–aspartic acid (RGD) motif recognizing the endothelial
integrin αvβ3 and triggering ligand endocytosis (Spitaleri
et al., 2008).
697ECound Dll1 promotes HSC expansion & engraftmentMaterial and methods
DNA recombination and production of recombinant
proteins
The cDNA fragment encoding the DSL domain (amino acids
126–224) of the mouse Dll1 (GenBank accession # BC065063.
1) was amplified by PCR using a mouse cDNA library as a
template. The product was fused at the C-terminus with a
RGD-encoding fragment (mD1R) or a stop codon (mD1S) by
PCR (supplementary Fig. 1A). The PCR primers are listed in
supplementary Table S1. The resultant gene fragments were
cloned into pET32a(+) between the Nco I and Xho I sites,
to construct pET32a-mD1R (RGD) and pET32a-mD1S (stop),
respectively. For the production of recombinant proteins,
Escherichia coli BL21(DE3) were transformed with the plas-
mids. Positive clones were expanded in Luria–Bertani (LB)
medium, and cells at the exponential stage were induced with
0.5 mM isopropyl β-D-thiogalactoside (IPTG). The Trx-tagged
proteins were purified by using Ni2+-NTA columns (Invitrogen,
Carlsbad, CA) according to the manufacturer's manual. To
obtain the S-tagged proteins, Trx-mD1S and Trx-mD1R were
cleaved by using thrombin (Novagen, Darmstadt, Germany),
and further purified using Ni2+-NTA columns. The human Dll1
DSL domain fused with RGD (hD1R) or stop codon (hD1S) was
prepared in a similar way.Cell culture
Human umbilical vein endothelial cells (HUVECs) were cultured
in M199 medium (GIBCO, Gaithersburg, MD) supplemented
with 20% fetal bovine serum (FBS), 30 μg/mL endothelial cell
growth supplement (ECGS) (Sigma, St Louis, MO), 20 units/mL
heparin, 100 U/mL penicillin, and 100 μg/mL streptomycin.
Cells between passages 3 and 5 were used for experiments. BM
cells were collected from mouse femurs and erythrocytes
were lysed with buffered 0.14 M NH4Cl. Cells were subjected
to negative selection for lineage negative cells (Lin−) by
using a Lineage Cell Depletion Kit (Miltenyi Biotec, Gladbach,
Germany). The Lin− cells were sorted with a FACS AreaTM flow
cytometer (BD Immunocytometry Systems, San Jose, CA) after
staining with anti-c-Kit-PE (2B8) and anti-Sca-1-APC (E13-161.7)
(Biolegend, San Diego, CA), to obtain c-Kit+Sca-1+Lin− (KSL)
cells. The KSL cells were N95% pure as determined by FACS. For
co-culture, HUVECs (2 × 104) were seeded in wells of 24-well
plates and cultured to confluence. Cells were treated with
mitomycin C (10 μg/mL) for 2.5 h, and were washed with PBS
thoroughly for 3 times. KSL cells (103) were then plated onFigure 3 mD1R accelerated hematopoietic recovery after irradiati
for 7 days. On the 14th day after the last injection, BM cells were a
(B) (n = 6). (C, D) Mice were sublethally irradiated, followed by dail
14th day after the last injection, BM cells were analyzed by FACS, w
BM cells (upper) and KSL cells (lower) were compared (D) (n = 6).
colony-forming assay (n = 4). (F) Histology of the femurs of mice in
immunohistochemistry. (G, H) C57BL/6-GFP mice were sublethally i
7 days. On the 14th day after the last injection, BM cells (2 × 105) we
mice, and were transplanted into lethally irradiated C57BL/6 mice.
of the recipient mice were analyzed by FACS, and the percentages
*P b 0.05, **P b 0.01.HUVECs and cultured in serum-free medium (StemSpan SFEM,
STEMCELL Technologies, Vancouver, Canada) supplemented
with a cocktail containing 5 types of mouse cytokines (m5GF)
including thrombopoietin (TPO, 20 ng/mL), stem cell factor
(SCF, 125 ng/mL), Flt-3 ligand (Flt-3L, 50 ng/mL), interleukin 6
(IL-6, 25 ng/mL) and IL-3 (10 ng/mL) (PeproTech, Rocky Hill,
NJ). Half of the amount of themediumwas changed every other
day. Seven days after the start of the co-culture, cells in
suspension were collected by gentle pipetting and analyzed
further. The recombinant mD1R or mD1S was added at the
concentration of 2.5 μg/mL. In some experiments, γ-secretase
inhibitor (GSI) (DAPT, Alexis Biochemicals, San Diego, CA) or
Dynasore (Sigma) was included at the concentration of 10 μM
or 50 μM, respectively, with DMSO as a control.
CD34+ human UCB progenitor cells were purified from
human UCB samples by FACS-sorting after staining with
anti-human CD34-FITC (#581, Biolegend). The cells (2 × 103)
were co-cultured on HUVECs in a similar way as described
above, with medium supplemented with the human cytokine
cocktail (h5GF) including TPO (20 ng/mL), SCF (120 ng/mL),
Flt-3L (50 ng/mL), IL-6 (5 ng/mL), and IL-3 (5 ng/mL)
(PeproTech, Rocky Hill, NJ). hD1R or hD1S was added at
the concentration of 2.5 μg/mL. Experiments associated with
human samples were approved by the Ethical Committee
on Medical Research-Related Affairs of the Fourth Military
Medical University.
BM and HSC transplantation
C57BL/6J and C57BL/6J-GFP mice were maintained in specific
pathogen free (SPF) conditions. For transplantation, female
mice 6 to 8 weeks old were irradiated lethally (900 cGy) or
sublethally (700 cGy) by total-body irradiation with γ-ray from
a 60Co irradiation apparatus. Freshly isolated BM cells or in vitro
expanded cells were infused via the tail vein. Mice were
then maintained with gentamycin sulfate-containing water
until further experiments. The homing efficiency of the
transplanted cells was estimated by using cells pre-labeled
with 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine
perchlorate (DiI) (Invitrogen). For limit dilution-competitive
repopulating unit (LD-CRU) assays, serial numbers of ex vivo
expanded hematopoietic cells (100, 500, 1000 cells) from
C57BL/6J-GFP mice were mixed with total BM cells (2 × 105)
derived from C57BL/6J mice, and transfused into lethally
irradiated C57BL/6J mice. Positively engrafted mice were
regarded to have ≥1% of donor-derived cells (GFP+) in the
peripheral blood 16 weeks after the transplantation. The
percentage of the negatively engrafted mice was plotted
against the initial numbers of cells infused. CRU frequency wason. (A, B) Normal mice were daily injected i.p. with PBS or mD1R
nalyzed by FACS. The numbers of the KSL cells were compared
y injection i.p. with PBS or mD1R for 7 days. On the 7th and the
ith the normal mouse BM cells as a control. The numbers of total
(E) BM cells from the mice in (C) (Day 14) were subjected to
(C) was examined on the 14th day by using H&E and anti-CD31
rradiated, followed by daily injection i.p. with PBS or mD1R for
re collected, mixed with BM cells (4 × 105) from normal C57BL/6
Eight weeks after the transplantation, the peripheral blood cells
of GFP+ cells were compared (H) (n = 5). Bars = means ± s.d.
698 D.-M. Tian et al.estimated by using the L-Calc software (STEMCELL Technolo-
gies) as the cell number by which 37% of the mice were non-
engrafted. To isolate single-cell suspensions of liver cells from
mice transfused with GFP+ BM cells, mice were perfused with
PBS. Livers were removed, weighed, and minced, followed by
filtering through a 70 μm nylon mesh to remove debris. After
washing with PBS, GFP+c-Kit+Lin− cells were sorted as above.
Serial numbers of GFP+c-Kit+Lin− cells (500, 1000, 2000 cells)
were mixed with BM cells (2 × 105) from C57BL/6J mice, to
perform the LD-CRU assay.
NOD/SCID mice were maintained in axenic conditions and
were sublethally (300 cGy) irradiated before the transfusion
of human-derived cells. Mice were then maintained in axenic
conditions until analyses. All animal experiments were ap-
proved by the Animal Experiment Administration Committee of
the Fourth Military Medical University.Colony-forming unit (CFU) assay
For the assessment of hematopoietic progenitor cells (HPCs),
CFU assay was performed bymixing freshly isolated or cultured
hematopoietic cells with Methocult GF M3434 medium or
Methocult GF H4434 medium (STEMCELL Technologies). Cells
were cultured for 12 or 14 days, and colonies (with N50 cells)
containing different lineages of cells were counted under a
microscope.Figure 4 mD1R facilitated donor cell engraftment in BM after B
and transplanted with 5 × 104 (□), 1 × 105 (○), 5 × 105 (◇), or 1 ×
transplantation, mice were daily injected i.p. with PBS or mD1R for
mice were transfused at each dosage of cells in each group. (B) BM ce
to CFU assay (n = 6). (C–F) BM cells from the recipient mice (5 × 105
for total GFP+ cells (D), GFP+c-Kit+Lin− cells (E), and GFP+ myeloid (C
*P b 0.05, **P b 0.01.Flow cytometry
FACS analysis was performed routinely by using a CaliburTM
flow cytometer (BD Immunocytometry Systems). Antibodies
are listed in supplementary Table S2. Dead cells were excluded
by staining with propidium iodide (PI). Apoptosis was analyzed
by using an Annexin V-FITC Apoptosis Detection Kit (4A Biotech,
Beijing, China).
Real time reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA was extracted by using the Trizol reagent
(Invitrogen). cDNA was prepared by using a kit from TOYOBO
(Osaka, Japan) with random primers. Real time PCR was
performed by using a kit (SYBR Premix EX Taq, Takara) and
the ABI Prism 7500 real time PCR system, with β-actin as
a reference control. Primers used in RT-PCR are listed in
supplementary Table S1.
Gene expression profiling
KSL cells were sorted from cells expanded in vitro in the
presence of PBS or mD1R for 7 days. Total RNA was extracted
and purified by using RNeasy micro kit (QIAGEN, GmBH,
Germany) following the manufacturer's instructions. MicroarrayM transplantation. (A) C57BL/6 mice were lethally irradiated
106 (△) BM cells from C57BL/6-GFP mice. From the day of BM
7 days, and the survival of the mice was plotted for 28 days. Ten
lls from the recipient mice (5 × 105 group) in (A) were subjected
group) in (A) were analyzed by FACS (C, supplementary Fig. S6)
D11b), B (B220) and T (CD3) cells (F) (n = 6). Bars = means ± s.d.
699ECound Dll1 promotes HSC expansion & engraftmenthybridization, data collection and analyses were fulfilled
by custom service provided by ShanghaiBio (Shanghai, China),
using Affymetrix mouse 430 2.0 array and GeneChip®
Scanner 3000 equipped with Command Console Software
3.1 (Affymetrix, Santa Clara, CA). Raw data were normalized
by using MAS 5.0 algorithm (Gene Spring Software 11.0,
Agilent Technologies, Santa Clara, CA). Hierarchical clustering
of samples was performed by using Cluster 3.0 software.
Original data were uploaded to the Gene Expression Omnibus
database (accession # GSE39082).
Histology
Tissues were fixed in 4% paraformaldehyde overnight.
Femurs were decalcified for 20 days using an EDTA de-
calcifying solution for paraffin section. H&E staining and
immunohistochemistry of bone sections were performed
using standard procedures. Rabbit anti-mouse CD31 and
horseradish peroxidase-conjugated goat anti-rabbit IgG were
purchased from Abcam (Cambridge, UK) and Boster BioTec
(Wuhan, China), respectively. Immunofluorescence staining of
cryosections and cultured cells were conducted following
standard protocols. Primary antibodies included rabbit anti-S
tag (Abcam), rat anti-mouse CD31 (Biolegend), rat anti-mouse
MECA-32, or rabbit anti-mouse c-Kit (Abcam). Secondary
antibodies were goat anti-rabbit IgG-Cy3, goat anti-rat
IgG-Cy3 (Boster BioTec), or goat anti-rabbit IgG-AMCA
(Cwbiotech, Beijing, China). Samples were counter stained
with 4,6-diamino-2-phenyl indole (DAPI) (Boster BioTec).
Images were taken under a fluorescence microscope (Olympus
BX51, Japan) or a confocal microscope (FV1000, Olympus).
For ultra structures, sample preparation was performed
following standard protocols. Samples were observed under
a scanning electron microscope (SEM) (S-3400N, Hitachi
Ltd., Tokyo, Japan) or a transmission electron microscope
(TEM) (JEM-2000EX, JEOL Ltd., Tokyo, Japan).
Statistics
Data were analyzed with the SPSS 17.0 software. Mouse
survival was analyzed by using the Kaplan–Meier analysis.
Comparisons between groups were undertaken by using the
unpaired Student's t test. Results were expressed as the
means ± standard deviation (s.d). P b 0.05 was considered
statistically significant.
Results
EC-targeted DSL domain of mouse Dll1 enhanced ex
vivo expansion of HSCs
To acquire a soluble and highly active soluble Notch ligand, we
generated a fusion protein composed of the DSL domain of
mouse Dll1 and a RGD motif (mD1R) (supplementary Fig. S1).
RGD recognizes integrin αvβ3 expressed on ECs and mediates
ligand endocytosis, an essential process for efficient Notch
activation (Fortini and Bilder, 2009; Meloty-Kapella et al.,
2012). Incubation of HUVECs with the recombinant proteins
showed that mD1R but not mD1S, the mouse Dll1 fused with a
stop codon, could bind to HUVECs (supplementary Fig. S2A).We tried to expand mouse HSCs ex vivo by using HUVECs
and hematopoietic growth factors (Butler et al., 2010;
Delaney et al., 2010b). Mouse BM c-Kit+Sca-1+Lineage−
(KSL) population cells (103) were co-cultured with HUVECs
supplemented with m5GF in the presence of PBS or mD1R.
mD1R upregulated Hes1 expression in the co-cultured hema-
topoietic cells in a γ-secretase-dependent way, suggesting
the activation of Notch signaling (supplementary Fig. S2B).
The activation of Notch signaling by mD1R appeared dose-
dependent within a range of protein concentrations (supple-
mentary Fig. S2C). Seven days after the starting of the
co-culture, mD1R induced a 7.96-fold more increase in the
total number of hematopoietic cells than the culture with
HUVECs + m5GF only (Fig. 1A). FACS analysis showed that the
percentage and the number of KSL cells increased significantly
in the culture with mD1R (Figs. 1B, C). The expanded cells
from each group were subjected to CFU assay. The results
showed that the total number of colonies and the numbers of
burst-forming unit-erythroid (BFU-E), CFU-granulocyte mac-
rophage (CFU-GM), and CFU-granulocyte erythrocyte mono-
cytemacrophage (CFU-GEMM) all increased significantly in the
culture with mD1R (Fig. 1D). Thus, in the presence of HUVECs
and m5GF, mD1R enhanced HSC expansion ex vivo.
It appeared that mD1R enhanced HSC expansion only at
certain concentrations (2.5 μg/mL in the present study)
(supplementary Fig. S3), because increasing the concentra-
tion of mD1R did not increase HSC expansion in a dose-
dependent way, possibly attributable to increased apoptosis
and differentiation as suggested by Delaney et al. (2005b).
We determined cell apoptosis in the ex vivo culture system
by using Annexin V staining followed by FACS. The result
showed that both mD1R and mD1S inhibited apoptosis that
occurred at a low level in the control culture without Notch
ligand (supplementary Fig. S4). This could be due to the fact
that low level of Notch activation by both mD1S and mD1R
could inhibit apoptosis, but only higher level of Notch
activation by mD1R could promote HSC expansion.
The expansion of HSCs in the presence of mD1R required
live HUVECs and direct cell–cell contacts between hemato-
poietic cells and HUVECs (data not shown). In the presence of
mD1R, hematopoietic cells contacted more closely with
HUVECs, forming niche-like structures with more cell–cell
adhesions (supplementary Fig. S5). Moreover, GSI or Dynasore,
an inhibitor of dynamin-mediated endocytosis, effectively
blocked the expansion of the total and KSL cells (Figs. 1E, F).
These results suggested that the ligand endocytosis-mediated
Notch activation was necessary for mD1R to enhance HSC
expansion.
KSL cells were sorted from cells expanded on HUVECs +
m5GF in the presence of PBS or mD1R. Comparison of the gene
expression profiles by using gene chip (representing 45,037
annotated genes) hybridization identified 1160 up-regulated
and 1164 down-regulated geneswithmore than 2-fold changes
in the mD1R group (Fig. 1G). Compared with the PBS group,
many known HSC markers (Slamf1, c-Kit, Cd34) and HSC
functional genes (Tal1, Gata2, Runx1, Cdkn1a, Jag1, Dtx3,
Hes1, Igf1, Procr, Hbegf, Vegfc, Tgif1) were upregulated,
while the genes related with differentiation (Tnfsf13b,
Ebf1) were downregulated in the mD1R group, as confirmed
by using real time RT-PCR (Figs. 1H, I) (Ivanova et al., 2002;
Ramalho-Santos et al., 2002; Zhong et al., 2005; Chambers
et al., 2007). These data indicated that HSCs expanded with
700 D.-M. Tian et al.
701ECound Dll1 promotes HSC expansion & engraftmentmD1R maintained their stemness better than those expand-
ed without mD1R.Increased repopulation ability of HSCs expanded in
the presence of mD1R
Freshly isolated BM KSL cells (Day 0) or KSL cells expanded on
HUVECs + m5GF ex vivo in the presence of PBS or mD1R were
labeled with DiI and were transfused into lethally irradiated
mice. The homing of the DiI positive cells to BM was
monitored by FACS 3 and 24 h post transfusion. KSL cells
expanded in the presence of mD1R showed significantly
increased homing to BM of the recipient mice (Fig. 2A).
We next determined the repopulation capacity of the
mD1R-expanded KSL cells by using the LD-CRU assay. Serial
numbers of GFP+ KSL cells expanded on HUVECs + m5GF in
the presence of PBS or mD1R were mixed with 2 × 105 BM
cells from C57BL/6J mice, and transfused into lethally
irradiated C57BL/6J mice. The percentages of GFP+ cells in
the peripheral blood were determined by FACS 16 weeks
later. The results showed a 6.1 fold higher frequency of
long-term repopulating cells in the mD1R-expanded popu-
lation (1/225, with a 95% confidence interval from 1/127 to
1/398) than that in the control (1/1373, with a 95%
confidence interval from 1/705 to 1/2670) (Fig. 2B). The
percentages of total GFP+ cells as well as GFP+ cells in
myeloid, B and T lineages increased in the recipient mice
transfused with cells expanded in the presence of mD1R
(Figs. 2C–E). These results suggested that themD1R-expanded
KSL cells had significantly increased repopulation activity.Direct injection of mD1R increased BM HSCs and
HPCs in vivo
Normal mice were injected i.p. daily with PBS or mD1R
(50 μg) for 7 days. On the 14th day after the last injection,
BM cells were analyzed by FACS. The result showed that
mD1R injection induced a mild but significant increase of BM
KSL cells (Figs. 3A, B).
Next, C57BL/6J mice were sublethally irradiated, and
injected i.p. daily with PBS or mD1R (50 μg) for 7 days. On the
7th and the 14th day after the last injection, mD1R-treated
mice showed a significant increase in total BM cells and KSL
cells compared with the PBS-treated mice (Figs. 3C, D).
Colony-forming assay of BM cells showed higher BM CFU
number in mD1R-treated mice than in PBS-treated mice
(Fig. 3E). Histological examination of BM by H&E staining and
anti-CD31 immunohistochemistry on day 14 showed that whileFigure 5 mD1R enhanced HSC engraftment in liver in BM trans
transplanted with 5 × 105 BM cells from C57BL/6-GFP mice. From the
mD1R for 7 days. Four weeks after the transplantation, the recipien
(A, supplementary Fig. S7). The numbers of total GFP+ cells (B), GF
quantified (n = 6). (E) The liver cells from mice in (A) were subjected
stained by immunofluorescence with anti-c-Kit plus anti-CD31 (F) or
indicate hematopoietic clusters and randomly docked cells, respect
TEM. HC, hematopoietic cells. (I, J) LD-CRU assay. GFP+c-Kit+Lin−
(A) were transfused into lethally irradiated C57BL/6J mice along w
16 weeks after the transplantation (n = 10) (I). The peripheral blood
different lineages (J). Bars = means ± s.d. *P b 0.05, **P b 0.01.the structure of BM from the PBS-treated mice was severely
damaged by radiation, with reduced cellularity and disorga-
nized and hemorrhagic sinusoid endothelial structures, these
damages were significantly repaired in BM of the
mD1R-treated mice (Fig. 3F). To functionally confirm the
repopulation activity of BM cells of irradiatedmice after mD1R
treatment, BM cells were collected from sublethally irradiat-
ed C57BL/6J-GFP mice treated with PBS or mD1R, mixed with
BM cells from C57BL/6J mice, and transfused into lethally
irradiated C57BL/6J recipients. Eight weeks later, FACS
analysis showed that BM cells of mD1R-treated mice exhibited
higher percentage of reconstitution than BM cells from
PBS-treated mice (Figs. 3G, H). These data suggested that
mD1R could promote BM recovery after irradiation.mD1R facilitated donor cell engraftment in BM
transplantation
Lethally irradiated C57BL/6J mice were transfused with
serial numbers of BM cells from C57BL/6J-GFP mice, and
were given PBS or mD1R daily from the day of BM
transplantation for 7 days. All mice transplanted with
5 × 104 BM cells died within 15 days. On the 28th day post
transplantation, the survivals of the mD1R-treated mice
receiving 1 × 105, 5 × 105 and 1 × 106 BM cells were 56%,
90%, 100%, compared with 0%, 30% and 50% of survivals in the
PBS-treated mice, respectively (Fig. 4A). The percentage of
donor-derived HSCs and HPCs (GFP+c-Kit+Lin−) engrafted in
BM increased significantly in the mD1R-treated mice
compared with the control, as assessed by colony-forming
assay (Fig. 4B) and FACS (Figs. 4C–E). The myeloid cells
(GFP+CD11b+) in BM increased most remarkably, compared
with the T (GFP+CD3+) and B (GFP+B220+) lineages (Fig. 4F and
supplementary Fig. S6). These results suggested that mD1R
improved donor cell engraftment in BM in transplantation.mD1R promoted HSC engraftment in the liver and
spleen in BM transplantation
C57BL/6 mice were lethally irradiated and were transfused
with BM cells (5 × 105) derived from C57BL/6-GFP mice. The
recipient mice were injected i.p. with PBS or mD1R daily
from the day of transplantation for 7 days, and hematopoi-
etic cells in liver were observed 4 weeks later. FACS analysis
of liver cells after perfusion showed that the numbers of
total GFP+ cells and GFP+c-Kit+Lin− cells increased signifi-
cantly in the livers of mice treated with mD1R compared
with the control (Figs. 5A–C). Colony-forming assay showedplantation. (A–D) C57BL/6 mice were lethally irradiated and
day of transplantation, mice were daily injected i.p. with PBS or
t mice were perfused, and the liver cells were analyzed by FACS
P+c-Kit+Lin− cells (C), and GFP+ myeloid, B and T cells (D) were
to CFU assay (n = 4). (F, G) Liver sections of the mice in (A) were
anti-c-Kit plus anti-MECA-32 (G). The yellow and white arrows
ively. (H) The ultra structures of the livers were observed under
cells (500, 1000, 2000 cells) sorted from the livers of mice in
ith BM cells (2 × 105) from C57BL/6J mice. CRU was estimated
cells of the mice (2000 cells group) were analyzed by FACS for
702 D.-M. Tian et al.that the number of CFU increased notably by cells from the
livers of the mD1R-treated mice after transplantation
(Fig. 5D). Analysis of the cells in different lineages indicated
that cells in myeloid, T, and B lineages all increased in thelivers of the mD1R-treated mice after transplantation
(Fig. 5E and supplementary Fig. S7). Similar situation was
observed in the spleens (supplementary Figs. S8A–6F).
These results suggested that mD1R treatment enhanced
703ECound Dll1 promotes HSC expansion & engraftmenthematopoiesis in the liver and spleen in addition to BM in
HSC transplantation.
We then examined the livers of PBS- or mD1R-treated
mice transfused with GFP+ BM cells by immunofluorescence
staining of endothelial markers (CD31 or MECA-32) and the
stem cell marker c-Kit. The result showed that in the livers
of PBS-treated mice the GFP+ cells scattered in the liver
sections. In contrast, many GFP+ cells formed clusters in the
livers of mD1R-treated mice (Figs. 5F, G). These cell clusters
were compact and in close association to micro-vessels, and
contained c-Kit+ cells, reminiscent of HSC and HPC clusters
found in fetal liver (Yokomizo et al., 2011; Zovein et al.,
2010). Similar hematopoietic clusters were also found in the
spleens of mice treated with mD1R after transplantation
(supplementary Fig. S8G). TEM observation further showed
that hematopoietic cell clusters under the endothelium of
hepatic micro-vessels were in close contact with ECs in the
liver of mD1R-treated mice (Fig. 5H). Such structure was not
found in the liver of the PBS-treated mice.
Single cell suspensions were then isolated from the livers
after perfusion, and GFP+c-Kit+Lin− cells were sorted by FACS.
Serial numbers of GFP+c-Kit+Lin− cells (500, 1000, 2000 cells)
were transfused into lethally irradiated C57BL/6J mice along
with total BM cells (2 × 105) derived from C57BL/6Jmice. CRU
was estimated 16 weeks after the transplantation. The result
showed significantly higher level of CRU in the livers of the
mice treated with mD1R than that of the control (1/743 versus
1/3069). Analysis of the peripheral blood of the recipient mice
showed that liver-derived cells could differentiate into
myeloid, T and B cells (supplementary Fig. S9). Therefore,
mD1R promoted hematopoiesis in the liver and spleen in BM
transplantation, likely through the formation of vascular
niche-like structures.Human D1R increased the expansion of human UCB
HSCs ex vivo
Human UCB CD34+ cells were collected, and cultured on
HUVECs + h5GF in the presence of PBS, hD1S, or hD1R for
7 days. Cell counting showed a remarkable increase of cell
number in the culture with hD1R compared with that in the
controls (Fig. 6A). FACS analysis indicated that the percent-
age and the number CD34+ cells increased significantly in the
culture with hD1R (Figs. 6B, C). Colony-forming assay
showed that hD1R-expanded cells exhibited significantly
higher number of CFU (Fig. 6D).
The expanded human UCB CD34+ cells (4 × 105 starting
cells) were transfused into sublethally irradiated NOD/SCID
mice. The engraftment of human CD45+ cells was examined
in the peripheral blood 4 and 8 weeks post transplantation.Figure 6 hD1R expanded human UCB HSCs. (A) CD34+ human UCB ce
or hD1R. The cells were harvested on day 7 and counted (n = 4). (B, C) T
(B) and the number (C) of CD34+ cells (n = 4). (D) The cells (1 × 103) in
(A) were transfused into sublethally irradiated NOD-SCID mice. The pe
8 weeks post transplantation (E). The percentages of engrafted huma
10,000 cells) were expanded as in (A), and were transfused into subl
analyzed by FACS 12 weeks post transplantation, and the percentages
of the recipient mice (10,000 cell group) in (G) were analyzed by F
compared (I). Bars = means ± s.d. *P b 0.05, **P b 0.01.The cells cultured in the presence of hD1R exhibited
significantly higher level of engraftment than the cells of
the control (Figs. 6E, F). Next, different numbers (2500,
10,000) of CD34+ UCB cells expanded with PBS or hD1R were
transfused into sublethally irradiated NOD/SCID mice. The
percentages of engrafted mice (with ≥0.5% human CD45+
cells in BM) were analyzed by FACS 12 weeks post trans-
plantation. In mice transplanted with cells derived from
2500 cord blood HSCs, hD1R-expanded human CD45+ cells
engrafted 50% of the mice (n = 8), while PBS-expanded
human CD45+ cells engrafted 37.5% of mice. In the 10,000
cell groups, these percentages were 100% and 75% for hD1R-
and PBS-expanded cells, respectively (Fig. 6G). Lineage
analysis showed that the human CD34+ HSPCs, CD33+
myeloid cells and CD19+ B-cells increased significantly in
mice receiving human cells expanded with hD1R than those
with PBS (Figs. 6H, I). These results indicated that hD1R
could effectively expand human UCB-derived HSCs ex vivo.Discussion
The DSL domain of Notch ligand is necessary and sufficient for
receptor binding and triggering (Fitzgerald and Greenwald,
1995). Both of the Notch extracellular domain fused with the
Fc region of immunoglobulin G and the DSL domain expressed
in E. coli have been developed as recombinant soluble Notch
ligands (Han et al., 2000; Varnum-Finney et al., 2000b). These
molecules have been employed to achieve artificial Notch
activation, therefore eliciting application potentials for ex
vivo HSC expansion. However, maximal Notch activation
requires ligand endocytosis in addition to ligand–receptor
binding (Fortini and Bilder, 2009; Meloty-Kapella et al.,
2012). In this study, we designed a new type of soluble Notch
ligand that is composed of the DSL domain of Dll1 and a RGD
motif, to meet these two requirements of Notch activation
(Spitaleri et al., 2008). D1R has a stronger activity to activate
Notch signaling (data not shown) and to enhance HSC
expansion ex vivo, likely due to the dynamin-dependent
endocytosis mediated by RGD–integrin αvβ3 interaction
(Caswell et al., 2009). Moreover, the RGD motif, which has
been employed in many fusion proteins targeting ECs for
therapeutic and diagnostic purposes (Avraamides et al.,
2008), may also provide EC-specificity of D1R. This peptide
can be manufactured in E. coli and purified conveniently,
providing a third advantage for its potential medical
applications.
Several studies including ours reported here demon-
strate the feasibility of soluble Notch ligands in the ex vivo
expansion of HSCs. Hematopoietic cytokines were essential
components for efficient HSC expansion in the presence oflls were cultured on HUVECs + h5GF in the presence of PBS, hD1S
he cells in (A) were analyzed by FACS to determine the percentage
(A) were used for colony-forming assay (n = 4). (E, F) The cells in
ripheral blood cells of the recipients were analyzed by FACS 4 and
n CD45+ were compared (F) (n = 6). (G) CD34+ UCB cells (2500 or
ethally irradiated NOD-SCID mice. BM of the recipient mice were
of engrafted human CD45+ cells were shown (n = 6). (H, I) BM cells
ACS (H). The percentages of different lineages engrafted were
704 D.-M. Tian et al.D1R, suggesting that Notch signaling might not replace the
roles of growth factors. Moreover, live HUVECs were also
necessary, consistent with previous conclusions (Butler et
al., 2010). In the presence D1R, HSCs and ECs formed closer
cell–cell contacts with more intercellular adhesion struc-
tures. HSCs in the presence of D1R showed stemness-related
gene expression profiles, suggesting that D1R might help
maintain the stemness of ex vivo expanded HSCs. Trans-
plantation experiments showed that HSCs expanded in the
presence of D1R repopulated recipients better. Therefore,
D1R could be employed for ex vivo expansion of HSCs in
transplantation therapies of related disorders.
UCB has been demonstrated as a source of HSCs for
transplantation therapy, but low number of HSCs in UCB,
at least partially, leads to delays in the rates and kinetics
of cell engraftment, especially the early generation of
neutrophils. Two categories of approaches have been
investigated to enhance the efficacy of UCB HSC trans-
plantation. One is to increase the number of infused cells
by ex vivo expansion or two UCB grafts, for instances. The
other is to modulate HSCs or the microenvironment to
enhance homing and engraftment of the infused HSCs
(Kelly et al., 2010; Delaney et al., 2010a). Our data
reported in the current study revealed that, in addition to
enhance ex vivo expansion of HSCs, D1R could directly
stimulate hematopoiesis in vivo in normal mice and
sublethally irradiated mice. Moreover, we found that the
application of D1R in vivo increased the engraftment of
HSCs after transplantation, leading to increased survival of
lethally irradiated mice receiving sub-optimal number of
HSCs. It is noteworthy that in mice injected with D1R,
there was a significantly increased myeloid repopulation
after HSC transplantation (Fig. 4F). These properties of
D1R suggest that this polypeptide has a potential to be
used in clinical therapy of human diseases such as
radiation-induced BM failure, and increases the efficiency
of HSC transplantation.
It seems that D1R improves HSC transplantation likely
through affecting both HSCs and their niches. Activation of
Notch signaling in HSCs by D1R bound to ECs might promote
HSC expansion principally through their enhanced prolifer-
ation, and decreased apoptosis might also contribute to
the ex vivo expansion to certain extent. The gene profiling
experiment indicated that D1R stimulated the expressions
of a group of stemness-related genes in HSCs, consistent
with a role of forced Notch activation in promoting HSC
expansion. In addition to the direct effects on HSCs, D1R
might also promote HSC engraftment through influencing,
structurally and/or functionally, stem cell niches. Ex vivo,
D1R promotes the formation of adhesive structures be-
tween HSCs and HUVECs, whose survival is necessary for
the expansion of HSCs. D1R significantly promoted the
recovery of the structure and organization of BM SECs after
radiation, consistent with the role of Notch signaling in
regulating EC proliferation and differentiation (Dou et al.,
2008). In addition to BM, the application of D1R also leads
to increased hematopoiesis in the liver and spleen, which
are hematopoietic tissues in rodents. D1R could bind to ECs
in BM as well as in the liver and spleen, and modulates their
activity in supporting HSCs. D1R might also modulate HSCs
to increase their homing to hematopoietic tissues. Notch
signaling regulates the expression of CXCR4, a criticalreceptor for HSC homing (Kelly et al., 2010; Delaney et al.,
2010a; Blank et al., 2008). Moreover, adhesion molecules
such as some members of the integrin family are critically
involved in HSC homing to BM niches (Wagers et al., 2002).
Indeed, the mRNA levels of the αv, α5, α6, and β1 integrins
were upregulated in the presence of mD1R compared with
that of the controls (supplementary Fig. S10). It is possible
that the interaction between HSCs and ECs mediated by
Notch signaling helped the homing and proliferation of
HSCs in the hematopoietic tissues including BM, spleen,
and liver of mice treated with D1R, because Notch
signaling has been demonstrated to crosstalk with many
important signaling pathways involved in stem cell niches
(Blank et al., 2008).
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